Kevin Outterson

Kevin Outterson

Auto-generated profile, based on publicly available information

Kevin Outterson

CARB-X, Boston University School of Law , Boston, MA 02215

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ETEvelina Tacconelli
Evelina Tacconelli
ECElena Carrara
Elena Carrara
ASAlessia Savoldi
Alessia Savoldi
SHStephan Harbarth
Stephan Harbarth
MMMarc Mendelson
Marc Mendelson
AZAnna Zorzet
Anna Zorzet

19 November 2019 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
UTUrsula Theuretzbacher
Ursula Theuretzbacher
KOKevin Outterson
Kevin Outterson
AEAleks Engel
Aleks Engel
AKAnders Karlén
Anders Karlén
Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.

19 November 2019 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
CAChristine Ardal
Christine Ardal
MBManica Balasegaram
Manica Balasegaram
RLRamanan Laxminarayan
Ramanan Laxminarayan
DMDavid McAdams
David McAdams
KOKevin Outterson
Kevin Outterson
NSNithima Sumpradit
Nithima Sumpradit

1 January 2016 in The Lancet
Verified
Journal Article
Closed access
CÅChristine Årdal
Christine Årdal
KOKevin Outterson
Kevin Outterson
SHSteven J Hoffman
Steven J Hoffman
AGAbdul Ghafur
Abdul Ghafur
MSMike Sharland
Mike Sharland
JRJohn-Arne Røttingen
John-Arne Røttingen

1 February 2015 in Health Affairs
Verified
Journal Article
Open access
PDF file
KOKevin Outterson
Kevin Outterson
JPJohn H. Powers
John H. Powers
GDGregory W. Daniel
Gregory W. Daniel
MMMark B. McClellan
Mark B. McClellan
Multidrug-resistant bacterial diseases pose serious and growing threats to human health. While innovation is important to all areas of health research, it is uniquely important in antibiotics. Resistance destroys the fruit of prior research, making it necessary to constantly innovate to avoid falling back into a pre-antibiotic era. But investment is declining in antibiotics, driven by competition from older antibiotics, the cost and uncertainty of the development process, and limited reimbursement incentives. Good public health practices curb inappropriate antibiotic use, making return on investment challenging in payment systems based on sales volume. We assess the impact of recent initiatives to improve antibiotic innovation, reflecting experience with all sixty-seven new molecular entity antibiotics approved by the Food and Drug Administration since 1980. Our analysis incorporates data and insights derived from several multistakeholder initiatives under way involving governments and the private sector on both sides of the Atlantic. We propose three specific reforms that could revitalize innovations that protect public health, while promoting long-term sustainability: increased incentives for antibiotic research and development, surveillance, and stewardship; greater targeting of incentives to high-priority public health needs, including reimbursement that is delinked from volume of drug use; and enhanced global collaboration, including a global treaty.

6 September 2016 in Annals of Internal Medicine
Verified
Journal Article
Closed access
DDDalia Deak
Dalia Deak
KOKevin Outterson
Kevin Outterson
JPJohn H. Powers
John H. Powers
AKAaron S. Kesselheim
Aaron S. Kesselheim
Because of the rising incidence of drug-resistant pathogens, legislation has been enacted to accelerate rapid development of new antibiotics. Using publicly available data, the authors examined the... A weak antibiotic pipeline and the increase in drug-resistant pathogens have led to calls for more new antibiotics. Eight new antibiotics were approved by the U.S. Food and Drug Administration (FDA...